Intelligent Bio Solutions (INBS) announced the submission of its Additional Information, AI, response to the United States Food and Drug Administration, FDA, as part of its ongoing 510(k) clearance process for planned entry to the U.S. market later this year. The response includes new positive data that strengthens the Company’s 510(k) submission and further validates the security and performance of its innovative fingerprint sweat-based drug screening technology. The Company’s updated submission incorporates data from intensive cybersecurity testing, including penetration and electromagnetic compatibility testing. These efforts have reinforced the system’s resilience across varied environments and supported targeted updates to further strengthen platform integrity and dependability.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INBS:
- Intelligent Bio secures major drug testing tender with transport operator
- Intelligent Bio Solutions Raises $3.8M Through Warrant Deals
- Intelligent Bio Solutions enters agreements to raise $3.8M in gross proceeds
- Intelligent Bio Solutions Advances Fingerprinting System for FDA
- Intelligent Bio Solutions announces new data on IFDDS